XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Information  
Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Three Months Ended

March 31, 

2025

    

2024

Program expenses related to clinical-stage product candidates

$

(4,217,214)

$

(5,912,029)

Program expenses related to preclinical and discovery programs

(30,600)

(108,338)

Personnel-related expenses (including stock-based compensation)

(1,397,874)

(1,194,687)

General and administrative professional and consultant fees

(444,865)

(369,353)

Other segment items¹

(192,128)

(225,400)

Interest income

187,612

44,168

Other non-cash income items²

558,000

6,698,692

Net Loss

$

(5,537,069)

$

(1,066,947)

¹ Other segment items included in net loss include insurance expenses, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.

² Other non-cash income items includes the change in fair value of our liability classified warrants.